ArticleBMC ophthalmology2025
Predictive impact of serous retinal detachment in refractory diabetic macular edema.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Early Switch to Dexamethasone Intravitreal Implant in Patients with Diabetic Macular Edema Poorly Responding to Anti-VEGF Therapy: A Narrative Review.Ophthalmology and therapy · 2026Review
- Analysis of OCT-Based Biomarkers and Recurrence in Eyes with Diabetic Macular Edema Following Anti-VEGF Therapy.International journal of general medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundAnti-vascular endothelial growth factor (VEGF) drugs are the first-line treatment option for DME management. However, part of DME was refractory to anti-VEGF medicine. With promotion of imaging technology, various retinal morphological characteristics are considered to be related to the prognosis of DME treatment. This study aimed to identify reliable predictive baseline morphological characteristics for refractory diabetic macular edema.
methodsThis retrospective study was to investigate refractory diabetic macular edema and were followed up for 6 months post-treatment. According to the treatment results, the cohort was divided into refractory or improved group. Baseline morphological characteristics were evaluated and analyzed using optical coherence tomography.
resultsSerous retinal detachment (63% vs. 25%, P < 0.05) and foveal eversion (77.8% vs. 41.7%, P < 0.05) are more common morphological characteristics in refractory DME than improved group. Binary logistic regression analysis showed average thickness of serous retinal detachment can predict the risk of refractory DME (OR = 1.052, 95% CI 1.005-1.102, P = 0.030). The area under the receiver operating characteristic curves for serous retinal detachment thickness was 0.922 (95% confidence interval 0.713-0.992).
conclusionPatients with refractory diabetic macular edema exhibited an increased incidence of baseline morphological characteristics, including serous retinal detachment and foveal eversion. The thickness of serous retinal detachment can serve as reliable quantitative biomarker, with diabetic macular edema displaying a serous retinal detachment thickness > 162 μm having a potential to become refractory in this study. This finding may promote early detection of refractory diabetic macular edema.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.